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Little is known about the content or quality of non-communicable disease (NCD) care in
humanitarian settings. Since 2014, Médecins Sans Frontières (MSF) has provided primary-
level NCD services in Irbid, Jordan, targeting Syrian refugees and vulnerable Jordanians
who struggle to access NCD care through the overburdened national health system. This
retrospective cohort study explored programme and patient-level patterns in achievement of
blood pressure and glycaemic control, patterns in treatment interruption, and the factors
associated with these patterns.
Methods and findings
The MSF multidisciplinary, primary-level NCD programme provided facility-based care for
cardiovascular disease, diabetes, and chronic respiratory disease using context-adapted
guidelines and generic medications. Generalist physicians managed patients with the sup-
port of family medicine specialists, nurses, health educators, pharmacists, and psychosocial
and home care teams. Among the 5,045 patients enrolled between December 2014 and
December 2017, 4,044 eligible adult patients were included in our analysis, of whom 72%
(2,913) had hypertension and 63% (2,546) had type II diabetes. Using visits as the unit of
analysis, we plotted the following on a monthly basis: mean blood pressure among hyper-
tensive patients, mean fasting blood glucose and HbA1c among type II diabetic patients, the
proportion of each group achieving control, mean days of delayed appointment attendance,
and the proportion of patients experiencing a treatment interruption. Results are presented
from programmatic and patient perspectives (using months since programme initiation and
months since cohort entry/diagnosis, respectively). General linear mixed models explored
factors associated with clinical control and with treatment interruption. Mean age was 58.5
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years, and 60.1% (2,432) were women. Within the programme’s first 6 months, mean sys-
tolic blood pressure decreased by 12.4 mm Hg from 143.9 mm Hg (95% CI 140.9 to 146.9)
to 131.5 mm Hg (95% CI 130.2 to 132.9) among hypertensive patients, while fasting glucose
improved by 1.12 mmol/l, from 10.75 mmol/l (95% CI 10.04 to 11.47) to 9.63 mmol/l (95% CI
9.22 to 10.04), among type II diabetic patients. The probability of achieving treatment target
in a visit was 63%–75% by end of 2017, improving with programme maturation but with
notable seasonable variation. The probability of experiencing a treatment interruption
declined as the programme matured and with patients’ length of time in the programme.
Routine operational data proved useful in evaluating a humanitarian programme in a real-
world setting, but were somewhat limited in terms of data quality and completeness. We
used intermediate clinical outcomes proven to be strongly associated with hard clinical out-
comes (such as death), since we had neither the data nor statistical power to measure hard
outcomes.
Conclusions
Good treatment outcomes and reasonable rates of treatment interruption were achieved in
a multidisciplinary, primary-level NCD programme in Jordan. Our approach to using continu-
ous programmatic data may be a feasible way for humanitarian organisations to account for
the complex and dynamic nature of interventions in unstable humanitarian settings when
undertaking routine monitoring and evaluation. We suggest that frequency of patient contact
could be reduced without negatively impacting patient outcomes and that season should be
taken into account in analysing programme performance.
Author summary
Why was this study done?
• Humanitarian actors have recently turned their attention to formally incorporating care
for chronic non-communicable diseases (NCDs) into their programmes. NCDs include
conditions such as hypertension (high blood pressure), heart disease, and diabetes.
• Little is known about the quality or effectiveness of current NCD programmes in
humanitarian contexts, and more research is needed around how to deliver good-qual-
ity NCD care to people affected by humanitarian crises.
What did the researchers do and find?
• Using routine clinic data, rather than research study data, we examined the levels of
blood pressure and diabetes control as well as treatment interruption among a group of
Syrian refugee and Jordanian patients attending a Médecins Sans Frontières (MSF) pri-
mary care clinic in north Jordan.
• Among 4,044 adult NCD patients eligible to be included in the study, 72% (2,913) had
hypertension and 63% (2,546) had type II diabetes.
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• Within both groups, disease control was achieved at about 63%–75% of monthly visits.
Clinical control varied by season; better blood pressure control was achieved in the hot
summer months. In addition, the chances of treatment interruption decreased both as
the programme matured and as individual patients remained longer in the programme.
What do these findings mean?
• Having taken account of multiple potential influencing factors in our analysis, we found
that the MSF programme was achieving good clinical results compared to previous pub-
lished literature.
• However, these good outcomes were achieved in the context of a complex and costly
programme and using conservative clinical targets.
• We suggest that (1) similar results may be possible while reducing the frequency of
patient visits, (2) our analysis approach may be useful for monitoring and evaluation of
complex programmes in unstable environments, and (3) season should be taken into
account when analysing NCD programme performance.
Introduction
Now into its ninth year, the Syrian crisis continues to ravage the Syrian population. Since
2011, over 6.1 million people have been internally displaced, while over 6.6 million people
have fled as refugees into the neighbouring countries Jordan, Lebanon, and Turkey [1]. Syria
has passed through an epidemiological transition. Before the conflict, non-communicable dis-
eases (NCDs) (mainly cardiovascular disease [CVD], cancer, chronic respiratory disease, and
diabetes) caused more deaths than infectious disease and accounted for 77% of total mortality
[2]. Host country and humanitarian health systems have had to adapt to new realities in
responding to the Syrian crisis: tackling a high NCD burden and reaching a mainly urban-
based (rather than camp-based) refugee population in the context of stressed local health sys-
tems [3–7].
Jordan hosts almost 670,000 United Nations High Commissioner for Refugees (UNHCR)
registered Syrian refugees and, globally, ranks second only to Lebanon in number of refugees
hosted relative to national population [1,8]. In addressing the rising NCD burden, Jordanian
health policy has shifted focus from secondary- or tertiary-level NCD care to strengthening its
primary NCD care delivery. Registered Syrian refugees are eligible to access Ministry of Health
(MOH) primary care NCD services, but financial barriers, complex care pathways and referral
systems, and limited health facility capacity have curtailed their access [7]. Jordan has enacted
sequential humanitarian policy changes during the crisis, initially providing free, limited pri-
mary care to Syrian refugees, adding user fees in 2014, and then increasing user fees to the full
‘foreigner rate’ in early 2018 [9]. In response, Syrian refugees have shifted care seeking from
the public sector towards non-governmental organisations (NGOs) and the private sector
[10].
Since 2014, Médecins Sans Frontières (MSF), a humanitarian medical organisation, has
provided primary-level NCD care for Syrian refugees and the host population at 2 clinics in
Irbid, in north Jordan. Humanitarian actors’ programmatic experience in NCD care delivery
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has grown in the last decade due to the increasing global NCD burden, current conflicts in sev-
eral middle-income countries of the Middle East, and the synergies between HIV, tuberculosis,
and NCDs [11,12]. In response to the limited evidence, guidelines, and tools available to guide
NCD interventions in low- and middle-income countries, especially for displaced, conflict-
affected populations, humanitarian actors are developing NCD-specific clinical and opera-
tional guidance and monitoring and evaluation tools [13–16]. The recent discourse around
quality of care and universal healthcare has underlined the importance of measuring quality
and effectiveness as primary-level NCD care is scaled up in humanitarian settings and in low-
and middle-income countries more broadly [17–20]. NCD programmes in humanitarian cri-
ses pose unique challenges for programme evaluation since they are often complex interven-
tions that rapidly adapt to volatile contexts. Routine data may be limited and of poor quality,
and accurate evaluation methods that involve minimal disruption to busy staff providing rou-
tine care are needed. Programmes with electronic health records, such as United Nations
Relief and Works Agency for Palestinian Refugees (UNRWA) clinics and some MSF settings,
have published descriptive cohort analyses of NCD cohorts involving quarterly or annual new
registrations and outcomes reporting [21–23].
MSF undertook a mixed methods evaluation of the Irbid NCD programme using the
RE-AIM implementation research framework [24]. In this paper, we explore the programme’s
effectiveness, from both programmatic and patient perspectives. For this we modelled the per
visit probability of achieving intermediate clinical targets, that is, blood pressure (BP) control
in adults with hypertension (HTN) and glycaemic control in patients with diabetes mellitus
type II (DM II). We also modelled the chances of treatment interruption. Finally, we explored
which factors (including patient, programme, and contextual factors) may have affected the
chances of a patient achieving clinical targets or of experiencing an interruption to their
treatment.
Our specific objectives were to (1) describe patterns in the attainment of intermediate clini-
cal targets (BP and glycaemic control) and treatment interruption, since the start of the pro-
gramme; (2) describe patterns in the attainment of intermediate clinical targets (BP and
glycaemic levels) and treatment interruption, from entry to the cohort (or from month of new




This was a retrospective cohort study that included all adult patients (18+ years) with a diagno-
sis of HTN and/or DM II who entered the MSF NCD programme in Irbid, Jordan, between 14
December 2014 and 31 December 2017 (see S1 Protocol).
Setting
The study was conducted in Irbid, the second largest city in Jordan, located 30 minutes south
of the border with Syria. Irbid governorate hosts over 165,000 Syrian refugees, who are mostly
urban-based and living amongst the host population [4]. MSF commenced an NCD pro-
gramme within a MOH primary care facility in Irbid, in north Jordan, in December 2014. A
second site in the city was opened within a local NGO clinic in April 2016. The MSF pro-
gramme was vertical, operating in parallel to the pre-existing activities at each site rather than
integrating with them. The cohort size was capped by MSF at approximately 4,000 for opera-
tional and cost reasons, and the service achieved coverage of about 23% of Syrian adult refu-
gees with NCDs in Irbid governorate [9].
PLOS MEDICINE Clinical outcomes in an MSF NCD programme serving Syrian refugees and the host population in Jordan
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003279 January 11, 2021 4 / 21
Participants
To be enrolled in the programme a person had to have a medical indication and a vulnerability
indication (Syrian refugee or vulnerable member of the Jordanian host population). Medical
indications included a history of HTN, established CVD (angina, myocardial infarction,
ischaemic stroke, transient ischaemic attack, peripheral vascular disease, congestive heart fail-
ure), diabetes mellitus type I or II, chronic obstructive pulmonary disease, asthma, or hypothy-
roidism. Vulnerability was defined as having refugee status, low income, and/or no Jordanian
public health insurance (thus required to co-pay for MOH services). Both medical and vulner-
ability enrolment criteria changed over time, for example isolated hypothyroidism was
removed as an enrolment criterion, and vulnerability criteria were adapted. There were no
limitations to enrolment in terms of place of residence or age. For this paper, only data of
patients with HTN and/or DM II, aged 18 years and older, were included in the analysis. Only
patients with HTN—either with a previously known diagnosis at programme entry or newly
diagnosed at enrolment or subsequent visits—contributed data to the BP control analyses.
Similarly, only DM II patients contributed data to the glycaemic control analyses.
Intervention
The MSF programme was a multidisciplinary, primary care model, which used context-
adapted clinical guidelines, medications based on the MSF and World Health Organization
(WHO) Essential Medicines List, and task sharing to nurses where appropriate. It served Syr-
ian refugees and vulnerable members of the Jordanian host population. The programme
evolved from initially providing medical consultation, health education, and behaviour change
counselling to also including individual- and group-based mental health and psychosocial sup-
port (MHPSS), a home visit service for house-bound patients, a humanitarian support worker
providing social work services, and physiotherapy services. Care was provided by non-special-
ist doctors, supported by a family medicine specialist at each clinic, along with a team of
nurses, trained health educators, psychosocial counsellors, pharmacists, physiotherapists, a
social worker, and a home care team. Programmatic changes introduced during the study
period included the initiation of task sharing to nurses of follow-up consultations for stable
patients and the introduction of formal MSF NCD guidelines (S2 Fig).
Most patients were enrolled during the first 6 months of the programme (S2 Fig). The
majority (over 90%) presented with established, self-reported diagnoses and were already on
treatment at enrolment; measurements and new diagnoses were made based on the MSF NCD
guidelines [16]. For hypertensive patients, BP was measured at each visit, and capillary fasting
blood glucose (FBG) was checked annually. For diabetic patients, BP and FBG were measured
at each visit, while glycosylated haemoglobin (HbA1c) was measured by an external laboratory
every 3 months. At the first visit, doctors recorded a complete past medical, medication, and
family medical history and performed a clinical examination. In addition, lifestyle CVD risk
factors (smoking status, alcohol intake, exercise levels) were recorded, the global cardiovascu-
lar risk score was calculated using WHO CVD risk prediction charts, acute complications
were identified and treated, long-term medications were prescribed for symptom management
and secondary prevention of complications, patients were referred for laboratory testing as
appropriate, and a follow-up interval was determined [25].
Follow-up visits involved reviewing patients’ symptoms and disease control, vital signs, and
laboratory results; determining and recording new diagnoses; adjusting and/or initiating med-
ications; and referring for further laboratory tests or to other health providers, as required.
Health promoters provided individually tailored health education at each clinical contact. At
enrolment, the doctor and health educator saw patients for 30 minutes each; patients on return
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visits spent approximately 15 minutes each with a clinician (either a doctor or nurse) and a
health educator. By the end of 2017, nurses were performing 6% of follow-up consultations for
stable patients, with doctors continuing to initiate and adjust all patients’ medications.
Variables
The main outcomes of interest were HTN control (<140/90 mm Hg) and glycaemic control
(capillary FBG� 180 mg/dl [10.1 mmol/l] or HbA1c< 8% [46 mmol/mol]). MSF and other
humanitarian actors have taken a consensus-based approach to developing guidelines, based
on international best practice. They adopted a more conservative HbA1c target than the inter-
national norm of 7% (53 mmol/mol) to avoid hypoglycaemia in insulin-treated patients (who
usually have no means to self-monitor in crisis settings) and used the same targets for all
patients, irrespective of age or comorbidity, to simplify clinical guidelines and delivery
[21,23,26]. Both FBG and HbA1c were used in this analysis since the FBG data were more
complete and the sensitivity of HbA1c appears to be reduced in Arab populations [27].
Treatment delay was defined as the difference in days between the planned next appoint-
ment date and the actual next visit date. Treatment interruption was defined as a treatment
delay greater than 31 days. If the planned appointment date was not registered, we assumed
this was 1 month from the previous visit if the patient was not achieving clinical targets at that
visit, and 3 months from the previous visit if the patient was achieving targets. We used the
variables ‘treatment delay’ and ‘treatment interruption’, rather than the operational definition
of ‘treatment defaulter’ included in our protocol, in order to capture periods of treatment
interruption followed by a return to care (S1 Protocol).
Data collection and management
Routine clinical data were maintained in paper-based, purpose-designed chronic care files,
stored securely at each clinic. On a weekly basis, MSF data clerks entered data into a password-
protected macro-based Excel software database specifically developed for the NCD pro-
gramme. Data from all patients aged 18 years and older with a new or established diagnosis of
HTN or DM II enrolled from December 2014 through to December 2017 in either of MSF’s
NCD clinics in Irbid were included. Data from both clinics were aggregated and analysed
using the statistical software R version 3.6.1 (2019-07-05).
Data analysis and reporting
We used visits as the unit of analysis when analysing the main study outcomes. This allowed us
to include all data from all patients, irrespective of their frequency or duration of attendance
or whether they had missed appointments. It also accounted for the fact that BP and glycaemic
control may vary from appointment to appointment.
Descriptive statistics were used to explore patient demographics at baseline and among
those who remained in care at 6 and/or 12 months post-enrolment.
To examine control from the programmatic perspective, we plotted the monthly means
across visits of systolic BP (SBP), the glycaemic variables (FBG and HbA1c), and the days of
treatment delay as defined above, for each month from December 2014 to December 2017. We
also plotted, for each month, the proportion of visits achieving BP and glycaemic control and
the proportion of visits after which there was an interruption of treatment (i.e., delay to next
visit of>31 days after the planned appointment).
To examine control from the patient perspective, we calculated the same means and pro-
portions in periods of 30 days from disease identification (enrolment visit for those with pre-
existing diagnoses, or the visit when a new diagnosis was made).
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To explore factors associated with the mean levels of SBP, FBG, and HbA1c; control of BP,
FBG, and HbA1c; and treatment delay/interruption at a given visit, we used 8 generalised lin-
ear mixed-effects models (GLMMs). For each of these outcomes, 2 models were adjusted: (1) a
linear model for the continuous level of the outcome and (2) a logistic model to estimate the
probability of the clinical target being reached or a treatment interruption occurring, as
defined above. A random effect coefficient was included to adjust for repeated patient visits.
The variables included in the models were time since patient’s diagnosis, time since beginning
of the programme, sex, age, Syrian versus other nationality, diabetes status (for models explor-
ing HTN control), HTN status (for models exploring glycaemic control), number of relevant
NCD conditions, number of MSF-prescribed NCD medications, history of previous treatment
interruption, and month of the year as a categorical variable (to account for seasonality). The
specific statistical models were not pre-specified. We have reported our results in accordance
with the STROBE checklist (S1 STROBE Checklist).
The London School of Hygiene & Tropical Medicine Ethics Review Committee (reference:
12239), the Médecins Sans Frontières Ethics Review Board, and the Jordanian MOH approved
this study. Consent was not obtained from the study participants as these routinely collected
programmatic data were analysed anonymously.
Results
From December 2014 to December 2017, 5,045 patients attended an enrolment visit at the
MSF NCD programme in Irbid, of whom 4,729 adult patients had an NCD targeted by the
programme and were actually enrolled. Among the 4,044 patients with HTN and/or DM II
(therefore, eligible for inclusion in the study), 2,913 (72%) had HTN and 2,546 (63%) had DM
II at baseline, while 1,530 (32.4%) had both diagnoses. Among those with HTN, 92.7% were
hypertensive at enrolment, and 7.3% were newly diagnosed at their first or subsequent visits;
the proportions were similar for DM II (90.8% at first visit and 9.2% at subsequent visits).
Table 1 presents HTN/DM II patients’ socio-demographics, cardiovascular risk factors, and
targeted NCD diagnoses (1) at enrolment, (2) among those who continued in care after 6
months, and (3) among those who continued in care after 12 months. Most were female (n =
2,432, 60.1%) and aged 41 years or older (mean = 58.5 years, SD = 11.6). Syrians made up
71.2% of included patients, while the remainder were mostly Jordanian. Of those with available
data, most had either primary-level or no formal education (n = 1,220, 30.3%, and n = 672,
16.6%, respectively), and many lived in households of 7 or more people (n = 1,590, 39.1%).
Over one-tenth (n = 446, 11.0%) defined themselves as mobility impaired, almost a quarter as
active smokers (n = 946, 23.4%), and only around a third (n = 1,493; 36.9%) as physically active
at enrolment. Over 80% (n = 3,341, 82.6%) of included patients attended a 6-month follow-up
appointment, while 76.9% (n = 3,109) attended a 12-month appointment. The demographic
profile of those attending was similar at baseline, 6 months, and 12 months.
Programmatic performance
Fig 1 shows patterns in the achievement of treatment targets and in the occurrence of treat-
ment interruption since the programme began in December 2014.
Hypertension. Among patients with HTN, mean per visit SBP decreased by 12.4 mm Hg
in the programme’s first 6 months, from a mean of 143.9 mm Hg (95% CI 140.9 to 146.9) in
December 2014 to 131.5 (95% CI 130.2 to 132.9) at 6 months, and by a further 1.6 mm Hg by
the end of the study period, with a mean of 129.9 mm Hg (95% CI 128.9 to 130.8) in December
2017 (Fig 1A). There appeared to be seasonal variation as SBP increased annually by 4 to 5 mm
Hg during the winter months (October to December).
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Table 1. Demographics, CVD risk factors, and NCD diagnoses among adult patients with hypertension and/or diabetes type II at enrolment and among those with
visits at 6 and 12 months.
Variable Baseline�
N = 4,044
Patients returning at 6 months^
N = 3,341
Patients returning at 12 months#
N = 3,109
n Percent n Percent or p-value n Percent or p-value
Age group (years) p = 0.665 p = 0.688
18–40 243 6.0 174 5.2 164 5.3
41–65 2,690 66.5 2,244 67.2 2,099 67.5
66–80 987 24.4 824 24.7 758 24.4
>80 121 3.0 96 2.9 86 2.8
No data 3 0.1 3 0.1 2 0.1
Sex p = 0.651 p = 0.947
Female 2,432 60.1 1,991 59.6 1,873 60.2
Male 1,612 39.9 1,350 40.4 1,236 39.8
Syrian p = 0.342 p = 0.064
No 1,166 28.8 998 29.9 960 30.9
Yes 2,878 71.2 2,343 70.1 2,149 69.1
Education p = 0.018 p< 0.001
No data 1,265 31.3 932 27.9 768 24.7
None 672 16.6 580 17.4 553 17.8
Primary 1,220 30.2 1,052 31.5 1,032 33.2
Secondary/higher 887 21.9 777 23.3 756 24.3
Household size p = 0.721 p = 0.185
No data 281 6.9 217 6.5 179 5.8
1–3 792 19.6 672 20.1 629 20.2
4–7 1,391 34.4 1,172 35.1 1,100 35.4
>7 1,580 39.1 1,280 38.3 1,201 38.6
Impaired mobility p = 0.508 p = 0.408
No data 123 3.0 87 2.6 80 2.6
No 3,475 85.9 2,891 86.5 2,699 86.8
Yes 446 11.0 363 10.9 330 10.6
Smoker p = 0.494 p = 0.517
No data 15 0.4 6 0.2 6 0.2
Never smoked 2,511 62.1 2,078 62.2 1,953 62.8
Ex-smoker 572 14.1 478 14.3 440 14.2
Current smoker 946 23.4 779 23.3 710 22.8
Exercise p = 0.997 p = 0.988
No data 228 5.6 190 5.7 177 5.7
Inactive 750 18.5 614 18.4 571 18.4
Moderate 1,573 38.9 1,306 39.1 1,221 39.3
Active 1,493 36.9 1,231 36.8 1,140 36.7
Hypertension p = 0.984 p = 0.961
No 1,131 28.0 936 28.0 872 28.0
Yes 2,913 72.0 2,405 72.0 2,237 72.0
Diabetes type II p = 0.839 p = 0.850
No 1,498 37.0 1,229 36.8 1,144 36.8
Yes 2,546 63.0 2,112 63.2 1,965 63.2
Diabetes type I p = 0.898 p = 0.722
No 4,023 99.5 3,322 99.4 3,090 99.4
Yes 21 0.5 19 0.6 19 0.6
(Continued)
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Rates of control similarly improved from only 26% (95% CI 20% to 32%) in the first month,
with a seasonal pattern. About 51%–60% of visits achieved BP targets in summer, decreasing
by about 6% to 46%–54% in winter (Fig 1B).
Diabetes. Among patients with DM II, mean per visit FBG similarly decreased from the pro-
grammatic perspective, by 1.12 mmol/l, from 10.75 mmol/l (95% CI 10.04 to 11.47) in December
2014 to 9.63 mmol/l (95% CI 9.22 to 10.04) at 6 months, and by a further 0.37 mmol/l to 9.26
mmol/l (95% CI 8.89 to 9.62) at 12 months (Fig 1C), which mirrors the increasing proportion of
visits achieving control over time since the programme began (Fig 1D). HbA1c control improved
markedly during the programme course, from a mean of 73.23 mmol/mol (95% CI 64.07 to
82.39) in month 1, with approximately 33% (95% CI 12% to 55%) of DM II patients achieving tar-
get, to a mean of 56.97 mmol/mol (95% CI 53.50 to 60.43), with 72% (95% CI 65% to 80%)
achieving control after the first 6 months of operation (Fig 1E and 1F). FBG control seemed to
worsen during the month of June, especially in 2017. HbA1c control appeared to show a similar
pattern of seasonality, with control deteriorating in the winter and improving in the summer.
Treatment interruption. The mean monthly days of delay following the next planned
appointment fell from 43 days (95% CI 20 to 66) in December 2014 to 14 days (95% CI 10 to
18) 12 months later and to only 3 days in December 2017. The probability of treatment inter-
ruption also showed a downward pattern, dropping from 0.07 (95% CI 0.04 to 0.10) in the first
month to 0.04 (95% CI 0.03 to 0.05) 12 months later.
Individual (closed) cohort analysis
Fig 2 shows the monthly pattern in clinical control from the patient perspective, starting with
the month of entry into the cohort, for those with established diagnoses, or the month when a
new diagnosis was made.
Hypertension. The mean SBP in hypertensive patients decreased by 6.6 mm Hg within
the first 6 months, from mean 137.9 mm Hg (95% CI 137.1 to 138.7) at entry/new diagnosis to




Patients returning at 6 months^
N = 3,341
Patients returning at 12 months#
N = 3,109
n Percent n Percent or p-value n Percent or p-value
CVD p = 0.483 p = 0.241
No 3,345 82.7 2,785 83.4 2,605 83.8
Yes 699 17.3 556 16.6 504 16.2
Asthma p = 0.491 p = 0.540
No 3,914 96.8 3,223 96.5 3,000 96.5
Yes 130 3.2 118 3.5 109 3.5
COPD p = 0.491 p = 0.680
No 4,008 99.1 3,317 99.3 3,085 99.2
Yes 36 0.9 24 0.7 24 0.8
p-Values compare distributions at 6 and 12 months with baseline distribution for each factor. Patients may have experienced treatment interruptions before returning at
either 6 months or 12 months, and the group returning at 12 months may contain patients who did not attend at 6 months.
�Refers to proportion of total eligible adult patients with hypertension/type II diabetes.
^Proportion of enrolled patients in each category returning at 6 months (±30 days).
#Proportion of enrolled patients in each category returning at 12 months (±30 days).
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; NCD, non-communicable disease.
https://doi.org/10.1371/journal.pmed.1003279.t001
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Fig 1. Programmatic patterns in achievement of clinical outcomes and in treatment interruption. (A) Mean monthly systolic
blood pressure (SBP; mm Hg) for all visits of patients with hypertension (HTN). (B) Proportion of visits per month of patients with
hypertension at which BP control was achieved. (C) Mean monthly fasting blood glucose (FBG) value (mmol/l) for all visits of
patients with diabetes mellitus type II (DM II). (D) Proportion of visits per month of patients with diabetes type II at which FBG
target was achieved. (E) Mean monthly glycosylated haemoglobin (HbA1c) value (mmol/mol) for all visits of patients with diabetes
type II. (F) Proportion of visits per month of patients with diabetes type II at which HbA1c target was achieved. (G) Mean monthly
days of delay (number of days after planned next visit that next visit actually occurred) for all visits of patients with hypertension
and/or diabetes type II. (H) Proportion of visits per month of patients with hypertension and/or diabetes type II at which a
treatment interruption occurred (next visit was>31 days after next planned visit date). Each panel reports the average per visit
value, using visits as the unit of analysis, for each month since the start of the programme (December 2014 to December 2017
inclusive). BP control was defined as BP< 140/90 mm Hg; control targets in patients with type II diabetes were capillary FBG� 180
mg/dl (10.1 mmol/l) or HbA1c< 8% (46 mmol/mol).
https://doi.org/10.1371/journal.pmed.1003279.g001
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Fig 2. Patterns in control of clinical parameters and treatment interruptions from the patient perspective. (A) Mean systolic
blood pressure (SBP; mm Hg) for all visits of patients with hypertension (HTN) per month since diagnosis. (B) Proportion of visits
per month of patients with HTN at which BP control was achieved. (C) Mean fasting blood glucose (FBG) value (mmol/l) for all
visits of patients with diabetes mellitus type II (DM II) per month since diagnosis. (D) Proportion of visits per month of patients
with diabetes type II at which FBG target was achieved. (E) Mean glycosylated haemoglobin (HbA1c) value (mmol/mol) for all visits
of patients with diabetes type II per month since diagnosis. (F) Proportion of visits per month of patients with diabetes type II at
which HbA1c target was achieved. (G) Mean monthly days of delay (number of days after planned next visit date that next visit
actually occurred) for all visits of patients with HTN and/or diabetes type II. (H) Proportion of visits per month of patients with
HTN and/or diabetes type II at which a treatment interruption occurred (next visit was>31 days after next planned visit date). Each
panel reports the average per visit value, using visits as the unit of analysis, for each month since diagnosis, for the reporting period
December 2014 to December 2017 inclusive. ‘Diagnosis’ refers either to the month of enrolment for patients who had a known
diagnosis on programme entry (90% of the cohort) or to month of new diagnosis for patients diagnosed at enrolment or at a
subsequent visit. BP control was defined as BP< 140/90 mm Hg; control targets in patients with DM II were capillary FBG� 180
mg/dl (10.1 mmol/l) or HbA1c< 8% (46 mmol/mol).
https://doi.org/10.1371/journal.pmed.1003279.g002
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improved from a baseline of 40% (95% CI 38% to 42%) to 54% (95% CI 52% to 57%) by
month 6 after entry/new diagnosis.
Diabetes. Similarly, there was a marked improvement in FBG level by 1.43 mmol/l from a
mean of 10.40 mmol/l (95% CI 10.19 to 10.62) at entry/new diagnosis to 8.97 mmol/l (95% CI
8.67 to 9.26) by 6 months; most of this improvement occurred within the first 3 months. From
month 4 onwards, patients with DM II achieved FBG targets at over 70% of visits. The pattern
in HbA1c (which reflects the previous 120 days of glycaemic control) was more variable. There
was a rapid decline in the first 6 months, from a mean of 64.56 mmol/mol (95% CI 62.93 to
66.19) at the first visit to a mean of 55.77 mmol/mol (95% CI 54.14 to 57.41) after 6 months,
but then a gentle slope upwards seemed to follow (Fig 2E). The percentage of visits where gly-
caemic control was achieved seemed to follow a similar pattern, with an increase in the first 6
months and then a levelling off or even a slight decrease in the following months (Fig 2F).
Treatment interruption. The mean number of days from the next planned appointment
to the actual visit almost halved, from 19.2 (95% CI 15.7 to 22.6) in month 1 to 10.9 (95% CI
8.6 to 13.3) 12 months after entry/new diagnosis.
Factors associated with clinical control and treatment interruption
In Tables 2 and 3 we report the multivariable linear and logistic regression analyses exploring
factors associated with achieving BP/SBP, FBG, and HBA1c targets (using continuous and
binary outcomes), with days of delay (continuous outcome), and with having at least 1 treat-
ment interruption (binary outcome).
Hypertension. Among patients with HTN, mean SBP was higher by 2.58 mm Hg for each
10-year increase in age (95% CI 1.99, 3.17; p< 0.001), by 1.43 mm Hg with comorbid diabetes
(95% CI 0.01, 2.85; p = 0.048), and by 1.92 mm Hg in the winter month of December (95% CI
0.27, 3.56; p = 0.022). However, visits with controlled diabetes and visits taking place in the
warmer months (May to September) were associated with a reduction in SBP of approximately
2–3 mm Hg. Having additional NCD conditions and receiving additional medications were
both associated with a small SBP reduction (less than 1 mm Hg), as shown in Table 2. Results
for the logistic regression were similar, with target BP less likely to be reached during the win-
ter months and more likely to be reached during the warmer months of the year.
Diabetes. Among patients with DM II, male sex, increasing age, years since diagnosis,
and having controlled BP were all strongly associated with improved FBG control. There was a
notable deterioration in the month of June, leading to a mean increase of 0.58 mmol/l (95% CI
0.35, 0.81; p< 0.001). Logistic regression results showed that in addition to the above factors, a
diagnosis of comorbid hypertension increased the odds of achieving target FBG. Improved
mean HbA1c was associated with increasing age, a comorbid diagnosis of HTN (and, if hyper-
tensive, with having controlled BP), and warmer months (May to September). Having a previ-
ous treatment interruption slightly increased mean HbA1c by 1.12 mmol/mol (95% CI 0.25,
2.00 p< 0.05). The same factors influenced whether the HBA1c target was reached.
Treatment interruption. The mean number of days the next visit took place after the
planned appointment date was significantly decreased by having had a previous treatment
interruption, with increasing age, and with maturation of the programme. Risk of delayed
attendance for the next appointment increased with time since enrolment/diagnosis, with each
additional NCD medication prescribed, with having a diagnosis of diabetes, and with having
FBG at target at the index appointment. It was not affected by calendar month. The risk of
treatment interruption decreased with time since enrolment/diagnosis and with each addi-
tional NCD diagnosis. It was increased by having a previous interruption (Table 3).
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Discussion
To our knowledge, this is the first study describing clinical outcomes in a primary-level NCD
programme for Syrian refugees and the vulnerable host population in Jordan. Overall, we
found that intermediate clinical outcomes improved, and the risk of treatment interruption
decreased, with programme maturation. From a programmatic perspective, the greatest gains
in SBP and FBG control occurred in the first 6 months of the programme. From a patient per-
spective, clinical parameters also improved in the initial months after entry into the pro-
gramme (or after diagnosis).
We found a marked seasonal variation in SBP control, with an increase in the mean of up
to 5 mm Hg during the colder winter months, which was confirmed by regression analyses.
An inverse relationship between ambient temperature and BP (with higher BP reported during
colder weather and vice versa) has been identified previously, but, to the best of our
Table 2. Multivariable linear regression models to explore factors associated with achieving control of intermediate clinical outcomes and on days of delay (continu-
ous outcomes).









Previous treatment interruption −0.02 (−1.21, 1.18) −0.02 (−0.19, 0.16) 1.12 (0.25, 2.00)a −6.92 (−10.34, −3.50)c
Male sex 0.75 (−0.57, 2.08) −0.42 (−0.65, −0.20)c −0.38 (−1.22, 0.47) 2.13 (−3.55, 7.81)
Age (per decade) 2.58 (1.99, 3.17)c −0.29 (−0.40, −0.19)c −0.75 (−1.17, −0.34)c −2.50 (−4.95, −0.04)a
Syrian versus other nationality 0.96 (−0.53, 2.46) 0.07 (−0.18, 0.32) −0.07 (−0.97, 0.84) 1.35 (−5.04, 7.74)
Per each year of programme −0.76 (−1.84, 0.32) −0.01 (−0.19, 0.17) 0.45 (−0.34, 1.25) −7.74 (−11.99, −3.50)c
Per each year since diagnosis −0.60 (−1.72, 0.51) −0.37 (−0.55, −0.19)c −0.10 (−0.89, 0.69) 5.80 (1.47, 10.14)b
Per additional NCD condition −0.56 (−1.09, −0.03)a −0.02 (−0.11, 0.06) 0.13 (−0.24, 0.51) −1.05 (−2.92, 0.82)
Per additional medication −0.20 (−0.37, −0.02)a −0.01 (−0.04, 0.02) −0.13 (−0.29, 0.03) 0.90 (0.39, 1.41)c
Hypertensive — −0.20 (−0.44, 0.04) −1.06 (−2.03, −0.08)a −0.44 (−6.02, 5.14)
Hypertensive, with controlled BP — −0.22 (−0.33, −0.11)c −1.00 (−1.68, −0.31)b 1.36 (−0.66, 3.37)
Diabetic 1.43 (0.01, 2.85)a — — 7.32 (1.61, 13.02)a
Diabetic, with controlled FBG −2.20 (−3.15, −1.25)c — — 4.74 (2.31, 7.18)c
February −0.00 (−1.72, 1.72) −0.18 (−0.42, 0.07) 0.06 (−1.58, 1.70) −3.37 (−7.80, 1.05)
March 0.27 (−1.45, 1.98) 0.09 (−0.15, 0.33) −0.03 (−1.53, 1.47) 2.84 (−1.59, 7.28)
April −0.74 (−2.42, 0.93) 0.09 (−0.15, 0.33) −0.39 (−2.02, 1.24) −0.65 (−5.02, 3.71)
May −2.10 (−3.74, −0.47)a −0.05 (−0.28, 0.18) −3.81 (−5.34, −2.27)c −1.04 (−5.26, 3.19)
June −2.25 (−3.85, −0.64)b 0.58 (0.35, 0.81)c −4.29 (−5.93, −2.64)c −0.10 (−4.27, 4.07)
July −2.37 (−4.06, −0.69)b 0.14 (−0.10, 0.38) −4.14 (−5.71, −2.58)c −3.17 (−7.52, 1.19)
August −2.78 (−4.38, −1.18)c −0.17 (−0.40, 0.06) −2.53 (−4.05, −1.01)b 0.11 (−4.04, 4.26)
September −1.73 (−3.43, −0.03)a −0.07 (−0.31, 0.17) −4.12 (−5.65, −2.58)c −2.05 (−6.44, 2.34)
October −0.60 (−2.27, 1.07) −0.04 (−0.27, 0.20) −1.38 (−2.90, 0.14) 0.91 (−3.39, 5.21)
November 0.95 (−0.75, 2.66) −0.17 (−0.41, 0.07) −0.61 (−2.21, 0.99) −1.79 (−6.18, 2.61)
December 1.92 (0.27, 3.56)a 0.04 (−0.19, 0.27) −0.62 (−2.10, 0.85) −0.88 (−5.14, 3.37)




BP control was defined as BP < 140/90 mm Hg; control targets in patients with diabetes mellitus type II were capillary FBG� 180 mg/dl (10.1 mmol/l) or HbA1c < 8%
(46 mmol/mol).
BP, blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated haemoglobin; NCD, non-communicable disease
https://doi.org/10.1371/journal.pmed.1003279.t002
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knowledge, this had not been reported in humanitarian settings [28–30]. The opposite was
true for diabetes control. The regression analyses showed the month of June was associated
with a marked deterioration in FBG control. There were no known programmatic or service
use changes, such as an increase in new patient intake (S2 Fig), to explain this, and we postu-
late that it may coincide with fasting during the holy month of Ramadan followed by the 3-day
Eid ul-Fitr festival [17].
From the patient perspective (the cohort analysis), the marked improvement in SBP control
within the first 6 months among patients with HTN (mean drop 6.6 mm Hg) is similar to that
seen in other studies [23,31]. A clear improvement within the first 6 months was also seen in
diabetic patients. Thereafter, time in programme or programme duration did not appear to
affect the odds of achieving glycaemic control. We note, however, that the proportion achiev-
ing the HbA1c target by month 12 (67%) was lower than the proportion attaining FBG control
(74%), potentially reflecting patients’ improved treatment adherence in the days around their
Table 3. Multivariable logistic regression models to explore factors associated with achieving control of intermediate clinical outcomes and with treatment inter-
ruption (binary outcomes).
Factor Effect: Odds ratio (95% CI)
BP control FBG control HBA1c control Treatment interruption
Previous treatment interruption 0.99 (0.84, 1.16) 0.96 (0.80, 1.16) 0.86 (0.76, 0.97)a 1.55 (1.15, 2.08)b
Male sex 0.88 (0.75, 1.02) 1.53 (1.24, 1.90)c 1.05 (0.94, 1.18) 1.06 (0.86, 1.31)
Age (per 10 years) 0.83 (0.78, 0.89)c 1.27 (1.15, 1.41)c 1.10 (1.03, 1.16)b 0.93 (0.85, 1.02)
Syrian versus other nationality 0.89 (0.75, 1.07) 0.99 (0.78, 1.25) 1.02 (0.90, 1.16) 0.95 (0.74, 1.22)
Per each year of programme 1.16 (1.02, 1.33)a 1.05 (0.88, 1.24) 1.00 (0.90, 1.12) 0.84 (0.67, 1.04)
Per each year since diagnosis 1.12 (0.98, 1.29) 1.39 (1.17, 1.67)c 0.97 (0.87, 1.09) 0.75 (0.58, 0.97)a
Per additional NCD condition 1.15 (1.08, 1.23)c 0.96 (0.88, 1.05) 1.01 (0.96, 1.07) 0.80 (0.71, 0.89)c
Per additional medication 1.03 (1.01, 1.06)b 0.98 (0.95, 1.01) 1.01 (0.98, 1.03) 1.03 (0.98, 1.08)
Hypertensive — 1.38 (1.10, 1.76)b 1.19 (1.04, 1.36)a 1.06 (0.82, 1.38)
Hypertensive, with BP controlled — 1.28 (1.14, 1.44)c 1.18 (1.07, 1.30)b 1.16 (0.94, 1.43)
Diabetic 0.90 (0.75, 1.07) — — 1.26 (0.93, 1.72)
Diabetic, with FBG controlled 1.34 (1.17, 1.53)c — — 1.21 (0.96, 1.54)
February 0.89 (0.70, 1.15) 1.23 (0.95, 1.60) 0.97 (0.78, 1.22) 0.92 (0.57, 1.50)
March 0.95 (0.74, 1.22) 0.94 (0.73, 1.22) 1.00 (0.81, 1.23) 0.94 (0.58, 1.52)
April 1.11 (0.87, 1.41) 1.03 (0.79, 1.33) 1.15 (0.92, 1.45) 1.01 (0.63, 1.61)
May 1.19 (0.94, 1.51) 1.12 (0.87, 1.44) 1.78 (1.42, 2.21)c 0.86 (0.54, 1.39)
June 1.17 (0.93, 1.47) 0.63 (0.49, 0.80)c 1.79 (1.41, 2.27)c 0.81 (0.50, 1.29)
July 1.20 (0.94, 1.53) 1.04 (0.80, 1.34) 1.55 (1.24, 1.94)c 0.90 (0.56, 1.47)
August 1.19 (0.94, 1.50) 1.38 (1.07, 1.77)a 1.32 (1.07, 1.63)a 1.09 (0.70, 1.70)
September 1.12 (0.87, 1.43) 1.14 (0.87, 1.48) 1.55 (1.24, 1.92)c 0.63 (0.37, 1.08)
October 1.10 (0.86, 1.40) 1.01 (0.78, 1.30) 1.01 (0.82, 1.25) 1.08 (0.68, 1.73)
November 0.81 (0.63, 1.03) 1.22 (0.94, 1.58) 1.12 (0.90, 1.40) 0.68 (0.40, 1.16)
December 0.73 (0.58, 0.93)a 1.04 (0.81, 1.34) 1.08 (0.88, 1.33) 0.68 (0.41, 1.14)




BP control was defined as BP < 140/90 mm Hg; control targets in patients with diabetes mellitus type II were capillary FBG� 180 mg/dl (10.1 mmol/l) or HbA1c < 8%
(46 mmol/mol).
BP, blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated haemoglobin; NCD, non-communicable disease.
https://doi.org/10.1371/journal.pmed.1003279.t003
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clinic appointments, as has been shown in other settings [32]. However, other potential expla-
nations concern the variable relationship between mean plasma glucose and HbA1c and the
individual variability in haemoglobin glycation rates, due to different erythrocyte longevity
and genetic factors, which may explain the apparent reduced HbA1c sensitivity in Arab popu-
lations [27,33].
Increasing age was associated with lower odds of achieving BP control. While BP rises with
age, and elevated BP generally requires additional classes and higher doses of antihypertensive
drugs over time, further work is needed to determine whether patients with uncontrolled
HTN had resistant HTN or whether they were undertreated. Conversely, increasing age and
having comorbid HTN were associated with better diabetes control. This may reflect the fact
that older patients with multi-morbidity received greater clinical attention or were more
adherent to treatment. These differences may have implications for programme planning as
the factors to consider in bringing about improvements in one clinical parameter may vary
from those for another.
Syrians made up approximately two-thirds of the cohort, and the remainder were mainly
Jordanian, reflecting Jordanian policy that access to humanitarian programmes should be
extended to the host population. In our analysis, nationality did not impact the odds of reach-
ing clinical targets, despite the Syrian cohort being more vulnerable, less educated, and gener-
ally poorer, with a decreased capacity to access care than their Jordanian counterparts, as
highlighted by other authors [10,34]. Having a previous treatment interruption was the main
risk factor for a further episode of treatment interruption, as might be expected, while the
number of days of delayed attendance decreased with programme maturation. It may be that
patients retained in the cohort were potentially more adherent than those who stopped attend-
ing, but this finding may also reflect the fact that clinic staff strongly emphasised adherence to
appointments, achieving a 90% attendance rate by 2017 (MSF data). Patients with FBG at tar-
get were more likely to delay attending their next planned appointment or to have a treatment
interruption yet maintained FBG control, perhaps highlighting that patients with controlled
diabetes could be given greater intervals between appointments.
The number of published studies that include outcomes on the clinical effectiveness of
NCD care models in humanitarian settings is growing from a low baseline [13]. UNRWA pub-
lished several cohort studies assessing clinical outcomes in cumulative and quarterly cohorts of
new admissions using an electronic medical record. They reported similar proportions achiev-
ing SBP< 140/90 mm Hg (76%) and glycaemic control (between 50% and 78%, using a target
of 2-hour postprandial glucose� 180 mg/dl [10.1 mmol/l]), with improved testing rates over
time but rising rates of loss to follow-up and complications [21,22,35,36]. Several studies of
MSF NCD cohorts using routinely collected clinical data have now been published utilising
different service models, lengths of follow-up, treatment targets, and statistical analyses
[23,31,37,38]. In integrated NCD/HIV programmes in Cambodia and in Kenya, 49.3% (n =
unknown) of non-diabetic hypertensive patients and 50% (n = 466) of HIV-negative patients
achieved SBP control (<140 mm Hg), while amongst Syrian refugees in Lebanon, 49% (n =
75) of non-diabetic hypertensive patients achieved BP targets (<140/90 mm Hg). In the Ken-
yan and Cambodia cohorts, less than a quarter (19% [n = 26] and 24% [n = 51]) reached the
target HBA1c of<7%, while, in Lebanon, 61% (n = 40) reached the more conservative target
of<8%, similar to our findings.
The HbA1c and FBG target levels used in this analysis, drawn from the MSF NCD guide-
lines, were less strict than international norms, which is reflected in the comparatively high
rates of control. If we reanalyse using a target HbA1c of<7% rather than <8%, the proportion
of visits meeting the target 6 months post-enrolment drops from 77% (95% CI 73%–82%) to
53% (95% CI 47%–58%). Since many patients in this study would have met the stricter
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treatment targets suggested by international bodies such as the American Diabetes Association
(HbA1c 6.5%–8%), it may be reasonable to introduce tighter, individualised treatment targets
for many patients in this context, as suggested in similar humanitarian settings [23,39].
We also note that the high levels of clinical control seen in this study were achieved in the
setting of a complex, facility-based, multidisciplinary programme and may reflect MSF’s sub-
stantial resources and programmatic experience. In addition, consultations, medications, and
laboratory investigations were provided free of charge to patients, as is MSF’s standard prac-
tice, which removed the main cost barrier to NCD care reported by Syrian refugees in Jordan
[9,10,34]. However, this service was limited in coverage (reaching only 23% of adults with self-
reported NCDs in Irbid governorate) and in scope, treating a limited number of medical con-
ditions [9]. Multiple studies have highlighted the complex, fragmented, and inadequate NCD
care available to Syrian refugees in Jordan and neighbouring host countries [7,10,40]. The high
cost of NCD care remains the principle barrier to the MOH, UNCHR, and other actors provid-
ing more comprehensive NCD services, while patients often face unaffordable co-payments
and transport costs to access existing services [7,10]. Qualitative data from our RE-AIM evalu-
ation confirmed that Syrian refugees in Jordan attempt to meet their perceived NCD care
needs by attending a mix of providers (public, NGO, and private facilities or pharmacies) and
by carefully balancing costs and household income [41]. When they are financially stretched,
they cope by rationing, borrowing, or begging, often depending on the generosity of the Syrian
and Jordanian communities [10]. Solutions to increase the coverage of high-quality, standard-
ised, and cost-effective primary-level NCD care and to improve access to essential secondary
and tertiary investigations and interventions are urgently needed.
Strengths and limitations
A key strength of this paper is that changes in clinical patterns were explored both using calen-
dar time (programmatic perspective), which may be useful for programme managers, and using
patients’ time in the programme (closed cohort approach), which is useful for clinicians. The
former allowed us to identify and adjust for seasonality in BP control, which a cross-sectional
approach at a single time point may have missed. Additionally, we maximised use of the rich,
continuous routine data collected by the programme at every patient visit, given that all enrolled
adults with HTN and DM II contributed data to the analysis, regardless of whether they had
periods of treatment interruption or were lost to follow-up. An additional important strength is
that we conducted a multivariable analysis using random effect models that explored the associ-
ation of patient, programme, and contextual factors with each of the outcomes.
The limitations include that this was a retrospective implementation study of a complex
intervention in an unstable humanitarian setting and, thus, subject to the significant challenges
inherent in performing evaluations in such contexts. These include using routine clinical and
programmatic data, which may have missing variables and be of limited quality. However, the
dynamic nature of the context and interventions preclude implementing more traditional
experimental designs (such as randomised controlled trials). Our study design did not allow us
to establish the causal mechanisms responsible for the reported outcomes or to attribute effec-
tiveness to individual programme components, but we explored associations that could be ana-
lysed in future studies [42,43]. We did not focus on other NCD comorbidities, such as chronic
respiratory disease and CVD, which are potentially more complex to diagnose and treat at the
primary care level and may have achieved less favourable outcomes [44]. We used intermediate
clinical outcomes to analyse programme quality since following up hard outcomes, such as
mortality and complication rates, requires time. Monitoring these hard outcomes is more com-
plex in humanitarian settings due to high attrition rates, mobile populations, and poor
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communication links with secondary care, where many NCD-related deaths are likely to occur.
Finally, our outcome results were compared to targets that had been adapted to the humanitar-
ian context and may not represent ideal targets for best clinical outcomes.
Implications for practice, policy, and research
Since a previous treatment interruption was the main risk factor for delayed appointment
attendance and future treatment interruptions, MSF could consider specific interventions and
strategies to support access and continuity of care for this group, ideally developed in consulta-
tion with them. For example, these may include person-centred options such as flexible open-
ing hours or decentralisation of certain aspects of care to the community level through use of
community adherence groups or technology to promote self-monitoring (eHealth). Limited
evidence shows that there is no benefit to reviewing stable patients more often than 6-monthly
(depending on severity, comorbidities, etc.), so service use could potentially be rationalised by
extending appointment intervals for those with good disease control [45].
MSF may also consider revising their BP and HbA1c targets in the Middle East population
to stricter, individualised treatment targets, in line with international norms, given the high
rates of control. The service may need greater focus on achieving SBP control in older patients,
as clinically appropriate. This may involve both exploring whether prescriber fatigue, patient
non-adherence, and/or resistant HTN are contributing to the poorer BP control in this group
and introducing individualised treatment targets. More lenient treatment targets may also
need to be considered during winter months. Diabetic patients could potentially benefit from
additional support and advice during Ramadan.
Further research is needed to improve monitoring and evaluation tools to (1) utilise the
continuous routine data being collected by some NCD programmes in humanitarian settings,
(2) determine the important components for quality assessment of these programmes, and (3)
explore the effectiveness of the individual components of NCD programmes and explore
causal mechanisms, nesting randomised controlled studies within programmes (for more nar-
row or specific questions) and using novel methodological approaches such as causal inference
frameworks appropriate to the evaluation of complex interventions.
Lessons learned around the implementation of this programme may be useful for the Jorda-
nian MOH system as it continues to strengthen primary-level NCD care. We note the increas-
ing role played by MSF nurses in health education, monitoring, and, more generally,
management of stable patients with NCDs. Given the pressure on the Jordanian health system
and the pull of the private sector and Gulf countries on Jordanian medical practitioners,
empowering nurses to play a greater role in the provision of primary-level chronic disease care
may be an option for policy makers, regulators, and training bodies to consider. We also note
that the positive results presented here were achieved in a relatively complex and costly pro-
gramme [46]. There may be scope to design and test simplified, more cost-efficient, person-
centred programmes that include features such as fixed dose combination therapy, reduced
frequency of clinic contact, decentralisation of care to the community, empowerment of
patients to self-care and to act as peer supporters, and increased use of technology in this tech-
savvy population [47]. Any such modifications to the care model would require careful evalua-
tion of their feasibility and acceptability to policy makers, practitioners, and patients.
Conclusion
In conclusion, we have added to the existing evidence base around the NCD disease burden
and barriers to accessing care among Syrian refugees in Jordan, by describing the content and
quality of a specific NCD programme designed to meet these patients’ needs. This study shows
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that good treatment outcomes and reasonable rates of treatment interruption can be achieved
in a multidisciplinary, primary-level NCD programme in north Jordan. We suggest that moni-
toring and evaluation of NCD programmes could be further improved by building on the anal-
ysis we have presented here. We also suggest that this comprehensive model of care could be
adapted to make it more person-centred, more cost-efficient, and more easily replicated in Jor-
dan and similar contexts in the Middle East.
Supporting information
S1 Fig. MSF Irbid NCD programme timeline.
(XLSX)
S2 Fig. Monthly new and follow-up appointments by nationality at the MSF NCD clinic in
Irbid, Jordan (January 2015 to December 2017).
(DOCX)






The authors gratefully acknowledge the patients and staff of the MSF NCD programme in
Irbid, Jordan, for their contribution to this work.
Author Contributions
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